


Claims

1. A combination comprising:

a) a compound of formula (I) or a pharmaceutically or veterinary acceptable salt thereof

5



10

(I)

wherein:

R₁ is phenyl substituted with halogen or trifluoromethyl, and further optionally substituted with one or two substituents selected from the group consisting of halogen, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, and halo(C₁-C₆)alkyl; or alternatively R₁ is pyrrolidin-1-yl;

15

R₂ is 2-oxo-pyrrolidin-1-ylmethyl or sulfamoylphenyl; and


R₃ is chosen from propyl, 1-methylethyl, butyl, 2-methylpropyl, pentyl, 1-methyl-butyl, 2-methylbutyl, hexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, and 1-methylpentyl; and

20

b) one or more drugs selected from the group consisting of:

(i) a compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof

25



30

(IV)

wherein R₅ is selected from hydrogen (H) and (C₁-C₆)alkyl, R₆ is selected from H, (C₁-C₆)alkyl and 2-(2,5-dioxopyrrolidin-1-yl)ethyl, wherein if R₅ is H, R₆ is other than H;

35

(ii) a sphingosine -1-phosphate receptor inhibitor (S1PR modulator); and


(iii) a Signal transducer and activator of transcription 3 (STAT3) inhibitor.

2. The combination according to claim 1, which comprises a compound of formula (I), and

a drug selected from the group consisting of a compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof, a S1PR modulator, and a STAT3 inhibitor.

- 5 3. The combination according to any of claims 1-2, wherein in the compound of formula (I), R_3 is 2-methylpropyl and R_1 and R_2 are as defined in claim 1.
4. The combination according to claim 3, wherein the compound of formula (I) is selected from the group consisting of:

10



5. The combination according to any of claims 1-4, wherein in the compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof, R_6 and R_5 are independently selected from hydrogen (H) and (C_1-C_6) alkyl and wherein at least one of R_6 and R_5 is (C_1-C_6) alkyl.
6. The combination according to any of claims 1-5, wherein the compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof is selected from the group consisting of dimethyl fumarate, and monoethyl fumarate.
7. The combination according to any of claims 1-4, wherein in the compound of formula (IV), R_6 is 2-(2,5-dioxopyrrolidin-1-yl)ethyl, and R_5 is methyl.
8. The combination according to any of claims 1-7, wherein the S1PR modulator is selected from the group consisting of fingolimod, siponimod, ozanimod, ponesimod, and ceralifimod.
9. The combination according to any of the claims 1-8, wherein the STAT3 inhibitor is selected from the group consisting of 2-Hydroxy-4-[[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]-benzoic acid, (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide, 4-((3-(Carboxymethylsulfanyl)-4-hydroxy-1-

naphthyl)sulfamoyl)benzoic acid, STAT3 Inhibitor Peptide of SEQ ID NO: 1, 6-Nitrobenzo[b]thiophene-1,1-dioxide, Ethyl-1-(4-cyano-2,3,5,6-tetrafluorophenyl)-6,7,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate, 5,15-Diphenylporphyrin, PIAS3 protein, N-(5-(Furan-2-yl)-1,3,4-oxadiazol-2-yl)-2-phenylquinoline-4-carboxamide, STAT3 Inhibitor XII SPI of SEQ ID NO: 2, and N-(1',2'-Dihydroxy-1,2'-binaphthalen-4'-yl)-4-methoxybenzenesulfonamide.

10. The combination according to any of claims 1-9, which is selected from:
the compound of formula (I) [N-(2-(2'-Fluorophenyl)ethyl)glycyl]-[N-(2-methylpropyl)glycyl]-
10 N-[3-(2'-oxopyrrolidinyl)-propyl]glycinamide, and dimethyl fumarate; or alternatively,
the compound of formula (I) [N-(2-(2'-Fluorophenyl)ethyl)glycyl]-[N-(2-methylpropyl)glycyl]-
N-[3-(2'-oxopyrrolidinyl)-propyl]glycinamide, and fingolimod; or alternatively,
the compound of formula (I) [N-(2-(2'-Fluorophenyl)ethyl)glycyl]-[N-(2-methylpropyl)glycyl]-
N-[3-(2'-oxopyrrolidinyl)-propyl]glycinamide, and 2-Hydroxy-4-[[[(4-
15 methylphenyl)sulfonyl]oxy]acetyl]amino]-benzoic acid.

11. The combination according to any of claims 1-10 comprising:
a) a compound of formula (I), or a pharmaceutically or veterinary acceptable salt thereof,
and
20 b) one or more drugs selected from the group consisting of: i) a compound of formula (IV),
or a pharmaceutically or veterinary acceptable salt thereof, ii) a S1PR modulator, and iii) a
STAT3 inhibitor, as previously defined,
wherein the amount of a) and the amount of b) in combination are therapeutically
effective.

25 12. The combination according to any of claims 1-11, wherein the amount of a) separately
is a subtherapeutic amount; and the amounts of a) and b) in combination are
therapeutically effective, being a subtherapeutic amount defined as the amount of a
particular compound below the therapeutic effective amount and for a particular disease.


30 13. The combination according to any of claims 1-11, wherein the amount of b) separately
is a subtherapeutic amount; and the amounts of a) and b) in combination are
therapeutically effective, being a subtherapeutic amount defined as the amount of a
particular compound below the therapeutic effective amount for a particular disease.

35 14. The combination according to any of claims 1-11, wherein the amount of a) and the
amount of b) separately are subtherapeutic amounts; and the amounts of a) and b) in
combination are therapeutically effective, being a subtherapeutic amount defined as the
amount of a particular compound below the therapeutic effective amount for a particular

disease.


15. A single pharmaceutical or veterinary composition which comprises a therapeutically effective amount of:

- 5 a) a compound of formula (I) or a pharmaceutically or veterinary acceptable salt thereof



(I); and

- b) one or more drugs selected from the group consisting of a compound of formula (IV) or a pharmaceutically or veterinary acceptable salt thereof, a S1PR modulator, and a STAT3 inhibitor
- 15



20 (IV);

together with one or more pharmaceutically or veterinary acceptable excipients or carriers; wherein the compound of formula (I) and one or more drugs are as defined in any of the claims 1-11, and wherein the amount of a) and the amount of b) in combination are therapeutically effective.

25

16. A package or kit of parts comprising:

- i) a first pharmaceutical or veterinary composition which comprises an amount of a compound of formula (I) as defined in any of claims 1-11, or a pharmaceutically or veterinary acceptable salt thereof, together with one or more pharmaceutically or veterinary acceptable excipients or carriers;
- 30 ii) a second pharmaceutical or veterinary composition which comprises an amount of one or more drugs selected from the group consisting of a compound of formula (IV), or a pharmaceutically or veterinary acceptable salt thereof, a S1PR modulator, and a STAT3 inhibitor, together with one or more pharmaceutically or veterinary acceptable excipients
- 35 or carriers; and
- iii) instructions for the use in combination of i) and ii);

wherein the first and second compositions are separate compositions, and wherein the amount of the compound of formula (I) of i) and the amount of one or more drugs of ii) in combination are therapeutically effective.

- 5 17. A combination as defined in any of claims 1-14, a single pharmaceutical or veterinary composition as defined in claim 15, or a package or kit of parts as defined in claim 16, for use in the treatment and/or prevention of an inflammatory neurological disease or condition which can result in the destruction or degeneration of axons or myelin in a subject in need thereof.